SMT202000222T1 - Adenovirus oncolitico che codifica per una proteina b7 - Google Patents
Adenovirus oncolitico che codifica per una proteina b7Info
- Publication number
- SMT202000222T1 SMT202000222T1 SM20200222T SMT202000222T SMT202000222T1 SM T202000222 T1 SMT202000222 T1 SM T202000222T1 SM 20200222 T SM20200222 T SM 20200222T SM T202000222 T SMT202000222 T SM T202000222T SM T202000222 T1 SMT202000222 T1 SM T202000222T1
- Authority
- SM
- San Marino
- Prior art keywords
- protein
- oncolytic adenovirus
- adenovirus encoding
- encoding
- oncolytic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507419.8A GB201507419D0 (en) | 2015-04-30 | 2015-04-30 | Virus |
| GBGB1516936.0A GB201516936D0 (en) | 2015-09-24 | 2015-09-24 | Virus |
| GBGB1522013.0A GB201522013D0 (en) | 2015-12-14 | 2015-12-14 | Virus |
| PCT/EP2016/059609 WO2016174200A1 (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
| EP16723043.2A EP3288573B1 (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000222T1 true SMT202000222T1 (it) | 2020-05-08 |
Family
ID=56008588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200222T SMT202000222T1 (it) | 2015-04-30 | 2016-04-29 | Adenovirus oncolitico che codifica per una proteina b7 |
Country Status (31)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3007711B1 (en) | 2013-06-14 | 2020-10-21 | Psioxus Therapeutics Limited | A dosing regime and formulations for type b adenoviruses |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| TR201802728T4 (tr) | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmıŠonkolitik adenovirĆ¼sler. |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| BR122018004815A2 (pt) | 2015-04-30 | 2019-09-10 | Psioxus Therapeutics Ltd | adenovĆrus oncolĆtico que codifica proteĆna b7 |
| MA43163A (fr) | 2015-11-02 | 2018-09-12 | Five Prime Therapeutics Inc | Polypeptides Ć domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer |
| EA201891022A1 (ru) * | 2015-12-17 | 2019-01-31 | ŠŃŠ°Š¹Š¾ŠŗŃŃŃ Š¢ŠµŃŠ°ŠæŃŃŃŠøŠŗŃ ŠŠøŠ¼ŠøŃŠµŠ“ | ŠŠøŃŃŃ, ŠŗŠ¾Š“ŠøŃŃŃŃŠøŠ¹ Š°Š½ŃŠøŃŠµŠ»Š¾ Šŗ ŠŗŠ¾Š¼ŠæŠ»ŠµŠŗŃŃ tcr ŠøŠ»Šø ŃŃŠ°Š³Š¼ŠµŠ½Ń ŃŠŗŠ°Š·Š°Š½Š½Š¾Š³Š¾ Š°Š½ŃŠøŃŠµŠ»Š° |
| CN117534735A (zh) * | 2016-03-31 | 2024-02-09 | ę¬§ę“²ååēē©å¦å®éŖ室 | č ŗē ęÆå¤å£³čē½č”ēééč½½ä½ |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | éæå”ē±³ęÆēē©å ¬åø | ęŗåø¦åē¹å¼ę§tē»čč”ę„åØēč ŗē ęÆ |
| CN117298260A (zh) * | 2016-09-02 | 2023-12-29 | č±čę©ęęÆå ¬åø | ēØDuoCARę²»ēēēēē»åē©åę¹ę³ |
| AU2017335673B2 (en) * | 2016-09-27 | 2024-11-14 | Sator Therapeutics LLC | Optimized oncolytic viruses and uses thereof |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| KR20190128050A (ko) | 2017-02-03 | 2019-11-14 | ģ ėė²ģķ° ģ¤ėø ķ¼ģø ė²ź·ø-ģ¤ėø ė ģ»¤ėؼģ°ģ° ģģ¤ķ ģ¤ėø ķģ“ģ“ ģėģ¼ģ“ģ | ģ¢ ģģ©ķ“ģ± ė°ģ“ė¬ģ¤ ģė² |
| JP2020517913A (ja) | 2017-04-28 | 2020-06-18 | ćć”ć¤ć ćć©ć¤ć ć»ć©ćć„ć¼ćć£ćÆć¹ļ¼ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼£ļ½ļ¼ļ¼ē“°čå¤ćć”ć¤ć³ććŖććććć«ććę²»ēę¹ę³ |
| KR20240132124A (ko) * | 2017-05-25 | 2024-09-02 | ģ ėė²ģķ° ģ¤ėø ģ¼ķøė“ ķė”ė¦¬ė¤ ė¦¬ģģ¹ ķģ“ė°ģ“ģ , ģøģ½ķ¬ė ģ“ķ°ė | ģ²ģ° ģ“ķ“ ģøķ¬ģ ģķ“ ģ¬ė©øķė ģ¢ ģ ģøķ¬ė„¼ ź°ģģķ¤źø° ģķ ģ ź·ķ ģ¢ ģģ©ķ“ ė°ģ“ė¬ģ¤ |
| CN120796389A (zh) | 2017-05-26 | 2025-10-17 | åē®ę£®ē¹Rxč”份ęéå ¬åø | ęŗåø¦č½¬åŗå ēéē»č ŗē ęÆ |
| WO2018220207A1 (en) | 2017-06-01 | 2018-12-06 | Psioxus Therapeutics Limited | Oncolytic virus and method |
| WO2019147921A1 (en) * | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| US12404312B2 (en) | 2018-03-05 | 2025-09-02 | Massachusetts Eye And Ear Infirmary | Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| EP3789489A4 (en) * | 2018-03-30 | 2022-01-05 | Tomoki Todo | ANTI-SWEEPER TYPE ONCOLYTIC VIRUS |
| CN119955743A (zh) * | 2018-09-10 | 2025-05-09 | äøęµ·é¦ęÆēē©ęęÆęéå ¬åø | äæ®é„°ēęŗ¶ē¤ē ęÆćå ¶ē»åē©åēØé |
| KR20210135532A (ko) * | 2019-03-05 | 2021-11-15 | ģģ ģøķ¬ | ģ ģ¹ė£ė„¼ ģķ ģ¢ ģ ģ©ķ“ ė°ģ“ė¬ģ¤ģ ģ©ė |
| EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | ķė”ė²¤ģ ė°ģ“ģ¤, ģøģ½ķ¬ė ģ“ķ°ė | ģ 1ķ ė¹ėØė³ģ ģė°©ķźø° ģķ ė°©ė² ė° ģ”°ģ±ė¬¼ |
| US20220249127A1 (en) * | 2019-05-14 | 2022-08-11 | Oncolys Biopharma Inc. | Method for administering oncolytic virus to tumor tissue, and device for administration |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| GB202102049D0 (en) * | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CN113544263B (zh) * | 2021-06-03 | 2022-12-06 | äøęµ·å č±ēē©å»čÆē§ęęéå ¬åø | ęŗ¶ē¤ē ęÆč½½ä½åå ¶åŗēØ |
| EP4404947A4 (en) | 2021-09-23 | 2025-12-10 | Sagittarius Bio Inc | Adenovirus and Methods of Using Adenovirus |
| EP4499846A1 (en) * | 2022-03-25 | 2025-02-05 | UniversitƤt ZĆ¼rich | Adenoviral mediated targeting of activated immune cells |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thƩrapie gƩnique. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | ęå°¼å ęÆčÆē©å ¬åø | ēØäŗčæē¤ę²»ēåé¢é²ēč“ē»čē åē ęÆ |
| DE69838510T2 (de) | 1997-02-20 | 2008-07-03 | Johns Hopkins University School Of Medicine | Mutationen in atp-abhƤngigen transpositionsproteinen die die zielortspezifitƤt reduzieren |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | ęå·čµē®ēē©ęęÆå¼åęéå ¬åø | åŗå å·„ēØč ŗē ęÆåå ¶ēØé |
| CA2342396A1 (en) * | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
| EP1137792B9 (en) | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| EP1816204B1 (en) | 1999-05-17 | 2010-10-20 | Crucell Holland B.V. | Recombinant Adenovirus of the Ad26 serotype |
| EP1181382B1 (en) | 1999-06-01 | 2005-03-23 | The University of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| KR100802403B1 (ko) * | 2000-01-21 | 2008-02-13 | ė°ģ“ģ¤ė²”ģ¤ ė¦¬ėÆøķ°ė | ė°ģ“ė¬ģ¤ ģ£¼ |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| EP1301612A2 (en) | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| EP1348030B1 (en) | 2001-01-04 | 2009-11-25 | Wadell, Gƶran | Viral vector for gene therapy |
| US20050175589A1 (en) * | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| AU2003206815A2 (en) * | 2002-02-01 | 2003-09-02 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with PODs |
| US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
| CN1705740B (zh) * | 2002-10-15 | 2013-07-24 | 佩å°Ā·ę¾å Ā·éå°å§ | å ·ęåååŗå č”Øč¾¾ēč ŗē ęÆåå ¶åŗēØ |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| CA2527369A1 (en) | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| WO2005118825A2 (en) | 2004-05-26 | 2005-12-15 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | ęé½åŗ·å¼ēē©ē§ęęéå ¬åø | čæē¤ē»čäøäøč”Øč¾¾å ē«č°čå ågm-csfēęŗ¶ē¤ę§č ŗē ęÆéē»ä½ēęå»ŗåå ¶åŗēØ |
| US20060292682A1 (en) * | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | ē»čåŗå ē³»ē»ęéå ¬åø | ēØäŗčæē¤ē»čå¢å¼ŗč½¬åƼēēŗ¤ē»“äæ®é„°ēč ŗē ęÆč½½ä½ |
| WO2006039045A2 (en) * | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | UniversitƤt Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| MX339014B (es) | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| CN101381742A (zh) * | 2008-10-23 | 2009-03-11 | ęµę±ēå·„å¤§å¦ | ęęåÆåØåé¶åę§č°ę§ęŗ¶ē¤č ŗē ęÆpCN305č½½ä½åå ¶ęå»ŗę¹ę³äøåŗēØ |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | FundaciĆ³ Privada Institut D'investigaciĆ³ BiomĆØdica De Bellvitge | Adenovirus oncolĆticos para el tratamiento del cĆ”ncer. |
| WO2011043719A1 (en) * | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| EP2606127B1 (en) | 2010-08-16 | 2019-03-20 | Salk Institute For Biological Studies | Adenoviral assembly method |
| EP2619312A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| EP2619224A1 (en) * | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| JP2015507604A (ja) | 2011-11-14 | 2015-03-12 | ćŖćøć§ćć¬ć¤ćć£ć ćµć¤ćØć³ć·ć¼ćŗļ¼ ćØć«ćØć«ć·ć¼ | ęøęæē²åééć·ć¹ćć ććć³ę¹ę³ |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | éč„æåøčå¤§å¦ | äøę„ę³ęå»ŗęŗåø¦å¤ęŗåŗå ēd24ēŗ¤ē»“čē½äæ®é„°ēę”件å¤å¶åč ŗē ęÆč½½ä½åå ¶åŗēØ |
| WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| TR201802728T4 (tr) * | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmıŠonkolitik adenovirĆ¼sler. |
| CA2931322A1 (en) | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) * | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| CN107406859A (zh) | 2015-03-17 | 2017-11-28 | å¾ęēē©å»ēå ¬åø | ē¼ē åē¹å¼ę§ęä½ēęŗ¶ē¤č ŗē ęÆåäøå ¶ēøå ³ēę¹ę³åēØé |
| BR122018004815A2 (pt) | 2015-04-30 | 2019-09-10 | Psioxus Therapeutics Ltd | adenovĆrus oncolĆtico que codifica proteĆna b7 |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | ŠŃŠ°Š¹Š¾ŠŗŃŃŃ Š¢ŠµŃŠ°ŠæŃŃŃŠøŠŗŃ ŠŠøŠ¼ŠøŃŠµŠ“ | ŠŠøŃŃŃ, ŠŗŠ¾Š“ŠøŃŃŃŃŠøŠ¹ Š°Š½ŃŠøŃŠµŠ»Š¾ Šŗ ŠŗŠ¾Š¼ŠæŠ»ŠµŠŗŃŃ tcr ŠøŠ»Šø ŃŃŠ°Š³Š¼ŠµŠ½Ń ŃŠŗŠ°Š·Š°Š½Š½Š¾Š³Š¾ Š°Š½ŃŠøŃŠµŠ»Š° |
| JP2019508044A (ja) | 2016-03-18 | 2019-03-28 | ćć³ćć»ć«ļ¼ć¤ć³ć³ć¼ćć¬ć¤ććć | ęعē¶ē“°čęęć®ććć®å¤ć¢ć¼ćććÆćæć¼ |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | éæå”ē±³ęÆēē©å ¬åø | ęŗåø¦åē¹å¼ę§tē»čč”ę„åØēč ŗē ęÆ |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018220207A1 (en) * | 2017-06-01 | 2018-12-06 | Psioxus Therapeutics Limited | Oncolytic virus and method |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/pt not_active Application Discontinuation
- 2016-04-29 HR HRP20200439TT patent/HRP20200439T1/hr unknown
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/ko active Active
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/da active
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/es unknown
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/ko not_active Withdrawn
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/ja active Active
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/pt active Search and Examination
- 2016-04-29 KR KR1020247006825A patent/KR102854512B1/ko active Active
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/lt unknown
- 2016-04-29 RS RS20200325A patent/RS60105B1/sr unknown
- 2016-04-29 PL PL16723043T patent/PL3288573T3/pl unknown
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/es unknown
- 2016-04-29 PT PT167230432T patent/PT3288573T/pt unknown
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en not_active Ceased
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/hu unknown
- 2016-04-29 EA EA201791971A patent/EA037611B1/ru unknown
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 ES ES16723043T patent/ES2780366T3/es active Active
- 2016-04-29 SI SI201630679T patent/SI3288573T1/sl unknown
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/zh active Active
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/es unknown
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/zh active Active
- 2016-04-29 KR KR1020257028976A patent/KR20250134212A/ko active Pending
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 SM SM20200222T patent/SMT202000222T1/it unknown
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
-
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/es unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/es unknown
- 2017-10-30 SA SA520412637A patent/SA520412637B1/ar unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/ar unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
-
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/es unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/ja active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
-
2020
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/el unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258044A (en) | Oncolytic adenovirus encoding the b7 protein | |
| IL260027A (en) | A group b adenovirus that encodes an anti-tcr-complex antibody or particle | |
| ZA201802261B (en) | Polypeptides | |
| PL3659614T3 (pl) | Onkolityczny wirus krowianki | |
| IL254577A0 (en) | polypeptides | |
| GB201713765D0 (en) | Modified adenovirus | |
| GB201409634D0 (en) | Intra block copy mode encoding choice | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| SG11201706882VA (en) | Polypeptides | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORĪ³) | |
| GB201417535D0 (en) | Adapting encoding properties | |
| IL267267A (en) | Vibration sensing system with wavelength encoding | |
| GB201401877D0 (en) | Peptides | |
| EP3239962A4 (en) | Encoding device | |
| GB2539417B (en) | Optimized multi-view image encoding | |
| GB201520655D0 (en) | Multi-mode sensor | |
| GB201614607D0 (en) | Modified adenovirus | |
| GB201706219D0 (en) | Modified adenovirus | |
| GB201700663D0 (en) | Modified adenovirus | |
| GB201401159D0 (en) | Adenovirus | |
| GB201516655D0 (en) | IX sensor | |
| GB201502178D0 (en) | Detecting polypeptides |